New data from the ILLUMINATE-A trial of lumasiran demonstrate the safety and efficacy of this RNA interference therapeutic in patients with primary hyperoxaluria type 1. Further studies are required to investigate the potential long-term benefits of this promising therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Garrelfs, S. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216–1226 (2021).
Danpure, C. J., Jennings, P. R. & Watts, R. W. E. Enzymological diagnosis of primary hyperoxaluria type I by measurement of hepatic alanine: glyoxylate aminotransferase. Lancet 329, 289–291 (1987).
Danpure, C. J. et al. An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J. Cell. Biol. 108, 1345–1352 (1989).
Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389–1399 (2019).
Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392–399 (2010).
Mandrile, G. et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 86, 1197–1204 (2014).
Monico, C. G. et al. Pyridoxine effect in type 1 primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 67, 1704–1709 (2005).
Santana, A., Salido, E., Torres, A. & Shapiro, L. J. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine: glyoxylate aminotransferase. Proc. Natl Acad. Sci. 100, 7277–7282 (2003).
Hoyer-Kuhn, H. et al. Vitamin b6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin. J. Am. Soc. Nephrol. 3, 468–477 (2014).
Luzzatto, L. et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet 392, 791–794 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.B.B. is a member of the scientific advisory board and has received personal fees from Alnylam Pharmaceuticals that are not related to this article. F.E. declares no competing interests.
Rights and permissions
About this article
Cite this article
Erger, F., Beck, B.B. A new era of treatment for primary hyperoxaluria type 1. Nat Rev Nephrol 17, 573–574 (2021). https://doi.org/10.1038/s41581-021-00449-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-021-00449-9
- Springer Nature Limited